Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardinal Health divests MedSystems

This article was originally published in The Gray Sheet

Executive Summary

Diversified healthcare supply firm Cardinal Health divests enteral device and surgical protection product maker MedSystems to private equity firm Linden LLC for undisclosed terms Sept. 2. Cardinal had acquired the business through its purchase of respiratory device firm Viasys in 2007 (1"The Gray Sheet" May 21, 2007, p. 7). MedSystems, which is being renamed Corpak MedSystems, "does not fit into the core focus of our clinical and medical products businesses," Cardinal explained. The Dublin, Ohio firm is also weighing a possible spin off of the $5.6 billion clinical and medical products unit (2"The Gray Sheet" Aug. 11, 2008, In Brief)

You may also be interested in...



Cardinal Builds Respiratory Franchise Through $1.5 Billion Viasys Purchase

Cardinal Health will gain ventilators to pair with its respiratory therapy consumable products through its $1.5 billion acquisition of Viasys Healthcare, announced May 14

Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel